Danimer Scientific
Producer of biopolymers manufacturer of PHA bioplastics from renewable, natural resources.
Launch date
Employees
Market cap
AUD61.3m
Enterprise valuation
AUD647m (Public information from Sep 2024)
Share price
$0.385 DNMR
Bainbridge Georgia (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 47.3m | 58.7m | 53.2m | 46.7m | 41.5m | 117m | 205m |
| % growth | 46 % | 24 % | (9 %) | (12 %) | (11 %) | 182 % | 75 % |
| EBITDA | (10.3m) | (88.8m) | (48.2m) | (95.8m) | (31.8m) | 3.6m | 18.6m |
| % EBITDA margin | (22 %) | (151 %) | (91 %) | (205 %) | (77 %) | 3 % | 9 % |
| Profit | (12.6m) | (60.1m) | (180m) | (155m) | (95.3m) | (61.7m) | (64.3m) |
| % profit margin | (27 %) | (102 %) | (338 %) | (333 %) | (230 %) | (53 %) | (31 %) |
| EV / revenue | 35.8x | 14.1x | 3.4x | 2.2x | 1.1x | 0.4x | 0.2x |
| EV / EBITDA | -164.5x | -9.3x | -3.8x | -1.1x | -1.4x | 12.7x | 2.4x |
| R&D budget | 7.9m | 20.3m | 31.9m | 29.2m | - | - | - |
| R&D % of revenue | 17 % | 35 % | 60 % | 63 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $2.1m | Seed | |
N/A | Debt | ||
$6.5m | Early VC | ||
| N/A | N/A | IPO | |
$350k | Grant | ||
* | N/A | $130m | Post IPO Debt |
* | N/A | $15.0m | Post IPO Equity |
* | $20.0m | Post IPO Debt | |
| Total Funding | AUD13.8m | ||
